Shares of clinical-stage biopharmaceutical company Syndax Pharmaceuticals (SNDX) fell 3.2% in early Monday trading. The company presented updated data for its revumenib combination therapy at the 2025 American Society of Hematology (ASH) annual meeting, demonstrating high response rates and minimal residual disease negativity in cohorts of newly diagnosed and post-transplant acute myeloid leukemia patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments